EuBiologics Co., Ltd. (KOSDAQ: 206650)
South Korea
· Delayed Price · Currency is KRW 10,360
+390 (3.91%)
Sep 11, 2024, 11:08 AM KST
EuBiologics Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Net Income | -13,879 | -13,879 | -1,099 | -27,574 | -60,134 |
| Depreciation & Amortization | 9,168 | 9,168 | 7,882 | 6,564 | 5,949 |
| Loss (Gain) From Sale of Assets | -1,666 | -1,666 | -193.28 | 0.88 | 5.24 |
| Asset Writedown & Restructuring Costs | 21,906 | 21,906 | 845.09 | 708.04 | - |
| Loss (Gain) From Sale of Investments | 200.32 | 200.32 | -2,142 | -253.29 | 180.59 |
| Loss (Gain) on Equity Investments | 512.58 | 512.58 | 321.04 | 124.61 | 0.15 |
| Stock-Based Compensation | 777.07 | 777.07 | 4,032 | 1,992 | 346.27 |
| Provision & Write-off of Bad Debts | -6.28 | -6.28 | 44.04 | -106.53 | 260.57 |
| Other Operating Activities | 2,192 | 2,192 | 3,531 | 19,866 | 52,844 |
| Change in Accounts Receivable | -2,747 | -2,747 | -700.88 | -1,144 | -1,775 |
| Change in Inventory | 3,754 | 3,754 | -6,679 | -5,153 | -1,643 |
| Change in Accounts Payable | -220.46 | -220.46 | 548.03 | -405.95 | -96.77 |
| Change in Other Net Operating Assets | 6,460 | 6,460 | 50.79 | -2,221 | 5,723 |
| Operating Cash Flow | 26,452 | 26,452 | 6,440 | -7,602 | 1,659 |
| Operating Cash Flow Growth | 310.73% | 310.73% | - | - | - |
| Capital Expenditures | -6,936 | -6,936 | -9,066 | -6,595 | -8,030 |
| Sale of Property, Plant & Equipment | 89 | 89 | - | 0.29 | 5 |
| Cash Acquisitions | - | - | - | -729.7 | - |
| Sale (Purchase) of Intangibles | -36,721 | -36,721 | -15,860 | -2,565 | -1,909 |
| Investment in Securities | 9.39 | 9.39 | 22,844 | -28,296 | -4,499 |
| Other Investing Activities | 15,128 | 15,128 | -136.27 | -31.84 | -76.91 |
| Investing Cash Flow | -28,110 | -28,110 | -2,132 | -38,244 | -15,245 |
| Short-Term Debt Issued | 2,663 | 2,663 | 6,000 | - | 5,402 |
| Long-Term Debt Issued | - | - | - | - | 4,000 |
| Total Debt Issued | 2,663 | 2,663 | 6,000 | - | 9,402 |
| Short-Term Debt Repaid | -2,507 | -2,507 | - | -2,300 | -901.82 |
| Long-Term Debt Repaid | -1,431 | -1,431 | -7,176 | -769.91 | -658.66 |
| Total Debt Repaid | -3,938 | -3,938 | -7,176 | -3,070 | -1,560 |
| Net Debt Issued (Repaid) | -1,274 | -1,274 | -1,176 | -3,070 | 7,841 |
| Issuance of Common Stock | 61.86 | 61.86 | 1,093 | 1,326 | 53,062 |
| Other Financing Activities | 1,779 | 1,779 | 717.31 | 1,031 | 104.41 |
| Financing Cash Flow | 566.03 | 566.03 | 634.58 | -712.61 | 61,008 |
| Foreign Exchange Rate Adjustments | -54.9 | -54.9 | -432.88 | 4.52 | -1.9 |
| Net Cash Flow | -1,147 | -1,147 | 4,509 | -46,554 | 47,421 |
| Free Cash Flow | 19,515 | 19,515 | -2,626 | -14,196 | -6,371 |
| Free Cash Flow Margin | 28.13% | 28.13% | -4.73% | -36.05% | -22.36% |
| Free Cash Flow Per Share | 535.44 | 535.44 | -72.15 | -400.46 | -227.38 |
| Cash Interest Paid | 746.56 | 746.56 | 566.16 | 554.79 | 512.78 |
| Cash Income Tax Paid | -37.16 | -37.16 | 3.25 | 43.52 | -3.41 |
| Levered Free Cash Flow | -30,178 | -30,178 | -18,184 | -34,456 | - |
| Unlevered Free Cash Flow | -29,873 | -29,873 | -18,024 | -34,088 | - |
| Change in Net Working Capital | -216.92 | -216.92 | 1,157 | 27,532 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.